Our patient profile 2023/24

The Christie is the largest single site cancer centre in Europe and the first in the UK to be accredited as a comprehensive cancer centre. 80% of our patients live in Greater Manchester, but over 8,000 patients travel from across the UK.

In 2023/24, The Christie saw 46,600 patients at one of our outpatient sites. 80% of these patients live in Greater Manchester, within one of the 10 Greater Manchester localities.

  • A graphic showing that in 2023/24, The Christie saw 46,600 patients. A map shows that 11% of patients live in the Manchester locality, 11% live in Stockport, 9% live in Tameside, 8% live in Bolton, 8% live in Wigan, 7% live in Trafford, 6% live in Oldham, 6% live in Rochdale, 6% live in Salford, 5% live in Bury, 15% live in Cheshire East, and 4% live in Cheshire West and Chester Unitary Authority areas. Text underneath the map reads that these figures include any patient attending at least one outpatient clinic appointment at any Christie site or outreach centre.

Gender

46,600 male and female patients (new and follow up) attended at least one outpatient clinic appointment this year. The most common cancers the Trust treats are prostate, breast, haematological and lower gastrointestinal (LGI) cancers. The average age of our patients is 65 years, with 40% being aged over 70 years. In England, in 2020, over half (56%) of all new cancers were diagnosed in people aged 70 years and over, according to NHS England Cancer Registration Statistics.

  • A graphic showing an icon of a man and woman, and a breakdown of Christie patient ages. Among male and female patients who attended outpatient appointments this year, the average age was 65 years. 1% of patients are less than 10 years old, 1% of patients are between 10 and 19 years, 3% are between 20 and 29 years, 6% are between 30 and 39 years, 9% are between 40 and 49 years, 17% are between 50 and 59 years, 24% are between 60 and 69 years, 27% are between 70 and 79 years, 11% are between 80 and 89 years and 1% are over 90 years old.
  • A graph showing a breakdown of Christie patients by disease group. The most common cancer types are haematological cancers seen in 13% of our patients (equating to 6,100 patients) and prostate cancers seen in 13% of patients (6,000 patients). Breast cancer is seen in 12% of patients (5,700 patients), lower gastric intestinal cancers are seen in 10% of patients (4,700 patients), gynaecological cancers are seen in 7% of patients (3,200 patients), endocrinology cancers and other endocrinology related issues are seen in 7% of patients (3,000 patients), lung cancers are seen in 6% of patients (3,000 patients), melanoma is seen in 5% of patients (2,500 patients), head and neck cancers are seen in 5% of patients (2,400 patients), non-prostate urological cancers are seen in 5% of patients (2,200 patients), neuroendocrine cancers are seen in 3% of patients (1,600 patients), central nervous system cancers are seen in 3% of patients (1,500 patients), sarcomas are seen in 3% of patients (1,400 patients), non-melanoma skin cancers are seen in 3% of patients (1,300 patients), other very rare cancers and benign tumours are seen in 3% of patients (1,300 patients), oesophageal cancers are seen in 2% of patients (1,100 patients), hepatobiliary tract cancers are seen in 2% of patients (1,000 patients), and germ cell tumours are seen in 2% of patients (800 patients).

Female patients

Half of our patients are female, with 35% of those being aged 70 or older. The most common cancers we treat for females are breast and gynaecological.

  • A graphic showing that 50% of Christie patients were female. Among female patients who attended outpatient appointments this year, the average age was 63 years. 1% of patients are less than 10 years old, 1% of patients are between 10 and 19 years, 3% are between 20 and 29 years, 7% are between 30 and 39 years, 11% are between 40 and 49 years, 20% are between 50 and 59 years, 23% are between 60 and 69 years, 23% are between 70 and 79 years, 11% are between 80 and 89 years, and 1% are 90 years and over.
  • A graphic showing the breakdown by disease group for female patients at The Christie. The most common cancer type seen in our female patients is breast cancer seen in 24% of female patients (equating to 5,600 patients). Gynaecological cancers are seen in 14% of female patients (3,200 patients), haematological cancers are seen in 12% of female patients (2,800 patients), lower gastric intestinal cancers are seen in 9% of female patients (2,200 patients), endocrinology cancers and other endocrinology related issues are seen in 8% of female patients (1,800 patients), lung cancers are seen in 7% of female patients (1,600 patients), melanoma is seen in 5% of female patients (1,200 patients), head and neck cancers are seen in 5% of female patients (1,100 patients), neuroendocrine cancers are seen in 4% of female patients (800 patients), central nervous system cancers are seen in 3% of female patients (700 patients), sarcomas are seen in 3% of female patients (700 patients), other very rare cancers and benign tumours are seen in 3% of female patients (600 patients), oesophageal cancers are seen in 2% of female patients (300 patients), hepatobiliary tract cancers are seen in 2% of female patients (400 patients), urological cancers are seen in 2% of female patients (500 patients), and non melanoma skin cancers are seen in 2% of female patients (500 patients).

Male patients

Half of our patients are male, with 44% of those being aged 70 or older. The most common cancers we treat for males are prostate and haematological.

  • A graphic showing that 50% of Christie patients were male. Among male patients who attended outpatient appointments this year, the average age was 67 years. 1% of patients are less than 10 years old, 2% of patients are between 10 and 19 years, 3% are between 20 and 29 years, 5% are between 30 and 39 years, 7% are between 40 and 49 years, 14% are between 50 and 59 years, 25% are between 60 and 69 years, 31% are between 70 and 79 years 12% are between 80 and 89 years, and 1% are over 90 years old.
  • A graphic showing the breakdown of cancer disease groups for male patients at The Christie. The most common cancer type seen in our male patients is prostate cancer seen in 26% of male patients (equating to 6,000 patients). Haematological cancers are seen in 14% of our male patients (3,300 patients), lower gastric intestinal cancers are seen in 11% of our male patients (2,500 patients), endocrinology cancers and other endocrinology related issues are seen in 7% of male patients (1,200 patients), lung cancers are seen in 6% of male patients (1,400 patients), melanoma is seen in 6% of male patients (1,400 patients), head and neck cancers are seen in 6% of male patients (1,300 patients), non prostate urological cancers are seen in 7% of male patients (1,700 patients), neuroendocrine cancers are seen in 3% of male patients (800 patients), central nervous system cancers are seen in 4% of male patients (800 patients), sarcomas are seen in 3% of male patients (700 patients), non melanoma skin cancers are seen in 3% of male patients (700 patients), other very rare cancers and benign tumours are seen in 3% of male patients (800 patients), oesophageal cancers are seen in 3% of male patients (800 patients), hepatobiliary tract cancers are seen in 2% of male patients (600 patients), and germ cell tumours are seen in 3% of male patients (800 patients).

NB: Endocrinology includes patients receiving care for endocrinology related issues as well as endocrine cancers.

Ethnicity

According to the ethnicity figures from the 2021 census and Gov.uk's UK population by ethnicity report, non-white minorities represent 23.6% of the Greater Manchester Population. 63% of our patients record themselves as the ethnicity category "White British" and 5% classify themselves as one of the non-white ethnic minority categories.

The differences between our Christie population and the Greater Manchester one may, at least in part, be due to a lower level of ethnicity data capture for our ethnic minority patients.

  • A graph showing that among The Christie patient population, 63.2% of patients (29,400 patients) classify themselves as white, 2.3% of patients (1,100 patients) classify themselves as Asian, 1.0% of patients (500 patients) classify themselves as Mixed ethnicity, 0.7% of patients (300 patients) classify themselves as Other ethnicity, 0.6% of patients (300 patients) classify themselves as Black, 0.3% of patients (200 patients) classify themselves as Chinese, and 2.4% of patients (1,100 patients) decline to provide an ethnicity status. Text underneath the graph reads that data completeness for ethnicity is 70%.

Religion

According to religious demographics from the 2021 census, the largest religious group in Greater Manchester is Christian who account for 47% of the population followed by Muslim, with 13% of the population.

Among our current patients, 40% are Christian and 2% are Muslim, with 7% reporting having no religion. However, there is a significant proportion of patients who did not disclose their religion.

  • A graph showing that for Christie patients who attended an outpatient appointment this year, 40% report themselves as Christian, 7% indicated they have no religion, 2% are Muslim, 1% are Jewish, less than 1% are Hindu, less than 1% are Buddhist, less than 1% are Sikh, and less than 1% declined to answer. Text underneath the graph reads that data completeness for religion is 51%.

Sexuality

According to the 2021 census sexual orientation statistics, 3.1% of the UK population (aged 16 years and over) describe themselves as gay, lesbian, bisexual or other sexual orientation. Among our patients, less than 1% are recorded as being lesbian, gay or bisexual (LGBTQ). However, there is a significant proportion of patients who did not disclose their sexuality.

  • A graph showing that for Christie patients who attended an outpatient appointment this year, 11.8% report themselves as straight or heterosexual, 0.2% indicated they are gay or lesbian, less than 0.1% are bisexual and 0.4% declined to answer. Text underneath the graph reads that data completeness for sexuality is 12.4%.

Disabilities

The Equality Act 2010 considers cancer a disability. Aside of cancer, just over 2,750(6%) of our current patients have disclosed one or more additional disabilities. There is a significant proportion of patients who did not disclose if they had any disabilities.

The most common additional disabilities reported were ‘long-term heath conditions’, such as diabetes, chronic obstructive pulmonary disease(COPD) and other heart and respiratory conditions. Over 400 patients reported more than one additional disability apart from cancer.

  • A graph showing that 3.5% of Christie patients who attended an outpatient appointment this year report themselves as having a long standing health condition, 0.8% report having a sensory impairment, 0.8% report having a physical impairment, 0.6% report having a mental health condition, and 0.2% report having a learning disability. Text underneath the graph reads data completeness is not applicable as The Trust only captures data for patients who have indicated they have a disability.

Deprivation​

35% of our patients live in the most deprived areas of Greater Manchester. Our measure of deprivation is based on the 2019 Index of Multiple Deprivation (IMD). IMD is the official measure of relative deprivation for small areas in England. The IMD combines information from the 7 domains to produce an overall relative measure of deprivation (see the English Indices of Deprivation 2019 FAQs for more).

  • A graph showing a breakdown of Christie patients by deprivation. Deprivation scores are commonly divided into deciles ranging from 1 being the most deprived to 10 being the least deprived. 15% of patients (equating to 6,500 patients) fall into the 1st decile i.e. the most deprived category, 10% (4,500 patients) fall into the 2nd decile, 10% (4,300 patients) fall into the 3rd decile, 8% (3,700 patients) fall into the 4th decile, 8% (3,600 patients) fall into the 5th decile, 8% (3,400 patients) fall into the 6th decile, 9% (3,900 patients) fall into the 7th decile, 11% (4,700 patients) fall into the 8th decile, 10% (4,400 patients) fall into the 9th decile, 12% (5,200 patients) fall into the 10th decile i.e. the least deprived.

Clinical outcomes: 30-day mortality post systemic anti-cancer treatment (SACT)

The Christie has similar 30-day mortality post systemic anti-cancer treatments (SACT) to the national average for all 3 cancer types evaluated (these are prostate, renal and breast). This data is produced by NHS England using data submitted by all NHS providers in England each month. Data is currently only available for 3 cancer types (please note: these evaluations are based on very small numbers of deaths).

  • A bar chart showing the 30-day adjusted mortality rates for post systemic anti-cancer treatment (SACT). At The Christie, prostate cancer has a 30-day adjusted mortality rate of 4.1% with a lower 2 standard deviation of 2.5% and an upper 2 standard deviation of 5.8%.  This is similar to the national average of 4.2%. At The Christie, renal cancer has a 30-day adjusted mortality rate of 12.6% with a lower 2 standard deviation of 9.1% and an upper 2 standard deviation of  15.7%. Again, this is similar to the national average of 12.4%. At The Christie, breast cancer has a 30-day adjusted mortality rate of 1.8% with a lower 2 standard deviation of 1.3 and an upper 2 standard deviation of 2.7%.  This is also similar to the national average of 2%.

The national data is from the NDRS report 30-day mortality post-Systemic Anti-Cancer Therapy - Case-Mix Adjusted Rates - NDRS for patients diagnosed with prostate cancer who received treatment between 2020 and 2022, for patients diagnosed with renal cell carcinoma who received treatment between 2019 and 2022 and for patients diagnosed with breast cancer who received treatment in 2021. Error bars represent 2 standard deviations.

Methodology

This data was produced by the clinical outcomes and data unit (CODU) at The Christie NHS Foundation Trust. It is has been created using data provided by NHS patients who had at least one outpatient clinic appointment at The Christie between April 2023 and March 2024. This includes new patients and those on treatment or follow-up.

Out of an average 60,000 patients coming through The Christie each year, the information presented here focuses on the approximate 47,000 NHS patients who attended at least one outpatient clinic appointment between April 2023 and March 2024.

Demographic data available here is predominantly generated from the ‘patient registration form’ provided to patients at the point of their first appointment at The Christie. The provision of these data by patients, at the point of registration, is optional. We also receive some data from general practitioners and other providers as part of the patient referral. Some protected characteristics, such as ethnicity, religion, disabilities and sexual orientation, have higher levels of missing data which is a recognized limitation of the information presented here.

The Christie is currently implementing several initiatives to improve the data collection process and engagement with all our patients.

Last updated: May 2024

© 2024 The Christie NHS Foundation Trust